One eye's AMD severity may affect AMD progression from the non neovascular to exudative form in the fellow eye.

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Age-related macular degeneration (AMD) is one of the leading causes of ... There are two main types: dry (atrophic) AMD and wet (neovascular) AMD. Dry AMD is more common, accounting for about 80–90% ...

This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...